Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
endTB: Evaluating New Regimens for MDR-TB
NCT02754765Phase 3Completed
- Sponsor
- Médecins Sans Frontières
- Start
- Dec 2016
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of bedaquiline, delamanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Médecins Sans Frontières. Started Dec 2016; status: completed.
02
Drugs
bedaquilinedelamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT02754765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754765.